Impact of community piped water coverage on re-infection with urogenital schistosomiasis in rural South Africa
- African Health Research Institute, South Africa
- University of KwaZulu-Natal, South Africa
- University of Cincinnati, United States
Abstract
Previously, we demonstrated that high coverage of piped water in the seven years preceding a parasitological survey was strongly predictive of Schistosomiasis haematobium infection in a nested cohort of 1,976 primary school children [1]. Here, we report on the prospective follow up of infected members of this nested cohort (N=333) for two successive rounds following treatment. Using a negative binomial regression fitted to egg count data, we found that every percentage point increase in piped water coverage was associated with 4.4% decline in intensity of re-infection (incidence rate ratio = 0.96, 95%CI: 0.93-0.98, P= 0.002) among the treated children. We therefore provide further compelling evidence in support of the scaleup of piped water as an effective control strategy against Schistosomiasis haematobium transmission.
Data availability
Data that support the findings presented in this manuscript are available from the African Health Research data repository upon request and agreeing to AHRI's terms and conditions for use. The datasets used here include homestead-level coordinates as an essential component and these data are personally identifiable. Request to access the data can be made through the AHRI's institutional website (https://www.ahri.org/research/#research-department) and by email to AHRI's data department (ITservicedesk@ahri.org).
Article and author information
Author details
Funding
National Institutes of Health
- Christopher Appleton
- Frank Tanser
Wellcome
- Frank Tanser
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Eduardo Franco, McGill University, Canada
Ethics
Human subjects: Ethical approval was provided by the Biomedical Research Ethics Committee of the university of KwaZulu-Natal (reference #E165/05). Written informed consent was sought from parents or guardians of the participating children for both rounds of follow-up in 2007 and 2008 and assent obtained from the children during the follow-up surveys.
Version history
- Received: November 29, 2019
- Accepted: March 10, 2020
- Accepted Manuscript published: March 17, 2020 (version 1)
- Version of Record published: March 31, 2020 (version 2)
Copyright
© 2020, Mogeni et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,045
- views
-
- 106
- downloads
-
- 8
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Impact of community piped water coverage on re-infection with urogenital schistosomiasis in rural South Africa
eLife 9:e54012.
https://doi.org/10.7554/eLife.54012
Further reading
-
- Medicine
- Microbiology and Infectious Disease
- Epidemiology and Global Health
- Immunology and Inflammation
eLife has published articles on a wide range of infectious diseases, including COVID-19, influenza, tuberculosis, HIV/AIDS, malaria and typhoid fever.
-
- Epidemiology and Global Health
Paxlovid, a SARS-CoV-2 antiviral, not only prevents severe illness but also curtails viral shedding, lowering transmission risks from treated patients. By fitting a mathematical model of within-host Omicron viral dynamics to electronic health records data from 208 hospitalized patients in Hong Kong, we estimate that Paxlovid can inhibit over 90% of viral replication. However, its effectiveness critically depends on the timing of treatment. If treatment is initiated three days after symptoms first appear, we estimate a 17% chance of a post-treatment viral rebound and a 12% (95% CI: 0–16%) reduction in overall infectiousness for non-rebound cases. Earlier treatment significantly elevates the risk of rebound without further reducing infectiousness, whereas starting beyond five days reduces its efficacy in curbing peak viral shedding. Among the 104 patients who received Paxlovid, 62% began treatment within an optimal three-to-five-day day window after symptoms appeared. Our findings indicate that broader global access to Paxlovid, coupled with appropriately timed treatment, can mitigate the severity and transmission of SARS-Cov-2.
